Barclays Downgrades Life Tech on Expected NIH Funding Cuts, Portfolio Concerns | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Barclays Capital today downgraded Life Technologies to an Equal Weight rating, citing the company's exposure to an anticipated soft academic and government funding environment and uncertainty about its sequencing portfolio.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: vervet genome, tandem repeats affect gene expression in great apes, and more.

Wired's Sarah Zhang writes that the fight over who developed the CRISPR/Cas9 genome editing tool first underscores the history of parallel discoveries in science.

Recent research indicates that the benefit of having a number of scientists all living and working in a certain area is eroding.

Tomas Lindahl, Paul Modrich, and Aziz Sancar share this year's Nobel Prize in Chemistry for their studies of DNA repair mechanisms.